The goal of the present study is to investigate the effectiveness of Condrosulf® 800 mg tablets vs. Placebo once a day for 6 months in the symptomatic treatment of finger joint osteoarthritis. Primary endpoints of the study are the evaluation of global spontaneous pain (Huskisson's Visual Analogue Scale: VAS) and the score of Dreiser's algo-functional index (FIHOA) during the treatment with the tested product, Condrosulf®, versus placebo. Condition or disease Intervention/treatment Phase Osteoarthrosis Drug: Chondroitin 4&6 sulfate (Condrosulf) Other: Placebo Phase 3. The goal of the present study is to investigate the effectiveness of Condrosulf® 800 mg tablets vs. Placebo once a day for 6 months in the symptomatic treatment of finger joint osteoarthritis in 160 randomised patients. Primary endpoints: Primary endpoints of the study are the evaluation of global spontaneous pain (Huskisson's Visual Analogue Scale: VAS) and the score of Dreiser's algo-functional index (FIHOA) during the treatment with the tested product, Condrosulf®, versus placebo.

FUNDAMENTALS OF MULTINATIONAL FINANCE Download Fundamentals Of Multinational Finance ebook PDF or Read Online books in PDF, EPUB, and Mobi Format. Click Download or Read Online button to FUNDAMENTALS OF MULTINATIONAL FINANCE book pdf for free now. Download free fundamentals of multinational finance moffett pdf converter. Fundamentals of Multinational Finance by Michael H. Moffett - PDF free download eBook. Fundamentals of Multinational Finance is intended for use in undergraduate.

Secondary endpoints are: Efficacy evaluation: Global impression of efficacy expressed by the patient and the physician (VAS), Grip strength (measured manometrically); Morning stiffness duration; Consumption of Paracetamol; Tolerability (4-point verbal scale); Adverse Events occurring during the treatment period; Other parameters:Treatment compliance; Biological markers of arthritis. Layout table for study information Study Type: Interventional (Clinical Trial) Actual Enrollment: 162 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment Official Title: Clinical Evaluation of Condrosulf 800 mg in the Treatment of Symptomatic OA of the Hand: a 6-month, Double-blind, Placebo Controlled Study Study Start Date: June 2005 Actual Primary Completion Date: December 2009 Actual Study Completion Date: August 2010. Inclusion Criteria: • Patients of either sex • Aged 40 and over • Outpatients • Patients fulfilling the ACR criteria for the reporting of hand OA • Patients showing X-ray features of hand OA on at least two joints (2 IP and/or 1 IP and 1 TMC) of the dominant hand on standard plain radiographs ( or = 40 mm at inclusion time). • Showing a FIHOA score > or = 6. • Having had at least two painful flares in a finger joint during the previous 12 month. • Patients who have signed the written informed consent for their participation in the study • Patients able to understand and follow the protocol. • Patients with a satisfying health and nutritional status.

• Female subjects of childbearing potential using, within three months prior to the inclusion in the study, a reliable form of contraception during the course of the study (oral contraceptive pill, intrauterine device or condoms) or female of non childbearing potential (hysterectomy, bilateral ovariectomy or tubal section/ligation). • Female subjects of childbearing potential with a negative urinary pregnancy test before the inclusion in the study.

May 30, 2017 - A 1998 pilot study found that Condrosulf 800 mg was an effective and safe slow-acting drug that reduced pain, increased mobility, and “might”.

See also: Use Chondroitin sulfate has been studied for the treatment of arthritis; however, information on its effectiveness is conflicting. It is commonly given in combination with other agents, such as glucosamine sulfate or glucosamine hydrochloride. It has also been studied for use in drug delivery, antithrombotic and extravasation therapy, treatment of dry eyes, and cystitis. Dosing Chondroitin sulfate has been administered orally for treatment of arthritis at a dosage of 800 to 1,200 mg/day. Positive results often require several months to manifest, and a posttreatment effect has been observed.,,,,,,,, Animal studies have suggested that the bioavailability of chondroitin sulfate may be increased when given multiple times a day. Contraindications Contraindications have not been identified.